Eidogen-Sertanty and Kalypsys Establish Drug Discovery Collaboration
News Dec 15, 2005
Eidogen-Sertanty, Inc. has announced that they have established collaboration with San Diego-based Kalypsys, Inc, focused on the discovery of small molecules for anti-inflammatory indications.
Under the terms of the collaboration, Eidogen-Sertanty will utilize its DirectDesign™ computational drug discovery platform to design a virtual library of synthetically tractable and drug-like compounds with predicted activity against a target of interest to Kalypsys.
The collaboration builds upon Kalypsys’ existing relationship with Eidogen-Sertanty as a customer of the Target Informatics Platform™ (TIP™).
"The team at Eidogen-Sertanty believes that our expertise in targeted library design will help deliver leads for Kalypsys’ small molecule pipeline," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.
"We are pleased to partner with Eidogen-Sertanty. Their technology appears to have great potential and we look forward to applying it to this research effort," stated Stewart Noble, VP of Chemistry at Kalypsys.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019